IDDF2022-ABS-0142 UHRF1-mediated NPY1R Gene Methylation Protects Intestinal Epithelial Cells Through Activation of Creb Signaling

Ya-Nan Han,Xiao-Hui Zhang,Li-Na Sun,Hao Liu,Hao-Hao Zhang,Xiao-Xia Ren,Fang-Fan Wang,Jie Chen,Yong-Zhan Nie,Ying Fang,Xiao-Di Zhao,Kai-Chun Wu
DOI: https://doi.org/10.1136/gutjnl-2022-iddf.57
2022-01-01
Abstract:Background Epigenetic modifications in intestinal epithelial cells (IECs) allow for precise control in intestinal homeostasis, the breakdown of which may precipitate the pathogenesis of inflammatory bowel disease (IBD). Here, we studied the role of UHRF1, a DNA methylation regulator, in intestinal epithelial homeostasis and IBD. Methods Tissues from UC patients and normal people were examined for UHRF1 expression. Colitis was induced using dextran sodium sulfate (DSS) treatment in UHRF1 conditional knockout or wild-type mice. CCK8 assay and flow cytometry were used to test proliferation and apoptosis rate, respectively. Target genes of UHRF1 were sifted by DNA microarray and methylation microarray, and validated by bisulfite sequencing and chromatin immunoprecipitation. Mechanism pathway were screened unbiasedly by phospho-kinase array. miRNAs targeting UHRF1-NPY1R axis were discovered by bioinformatics prediction and validated by dual-luciferase reporter assay. Results UHRF1 expression was downregulated in UC patients, colitis models and inflammation-induced cells. UHRF1 was found to be important in maintaining intestinal epithelial cells viability and inhibiting cytokine production, in vitro. Also, UHRF1 functioned in the intestinal epithelium and prevented intestinal inflammation, in vivo. Mechanistically, UHRF1 could inhibit inflammation by hypermethylating NPY1R promoter, leading to CREB pathway activation and NF-κB activity inhibition. Moreover, miR-141 was a potential therapeutic anti-inflammatory target by targeting NPY1R signaling. Conclusions Both UHRF1 and miR-141 protect mice from intestinal inflammation by epigenetically regulating NPY1R-associated inflammatory signaling in IECs. Targeting of miR-141 or UHRF1 may represent a novel therapeutic approach in IBD.
What problem does this paper attempt to address?